what will happen if i stop taking glutathione pigmentation and dark spots are on your skincare list, here’s something I’ve been trying lately🤍, @drsheths Lipo-Gluta & Alpha Arbutin Serum has a really interesting dual-chamber design that keeps what happens when you stop

It has been proposed that melittin might help address neurodegenerative disorders linked to stimulation of microglial cells since it substantially inhibits BV2 microglias pro-inflammatory activities (Zhang et al., 2024)

Potent method for the simultaneous determination of glutathione and hydrogen peroxide in mitochondrial compartments of apoptotic cells with microchip electrophoresis-laser induced fluorescence

While most people get enough B12 through diet, certain groups might benefit from B12 injections or supplements

waiting for funding

Ongoing low-dose maintenance (experimental) Continuous dosing approach: Dose: 1-2mg daily OR 3-5mg 2-3x weekly Duration: Ongoing (not cycled) Goal: Maintain constant telomerase activation Status: Experimental, not from research protocols Rationale: Telomerase needs continuous activation to maintain telomere length Cyclic dosing may allow regression between cycles Low-dose continuous might provide stable benefits Similar to maintenance protocols for other peptides Continuous dosing options: Advantages of continuous: No "off" periods where benefits regress Potentially stronger cumulative anti-aging More like natural physiologic regulation Easier to stack with other peptides Disadvantages: Much higher annual cost ($1,800-3,600 vs $300-600) No long-term safety data Uncertain if better than cyclic approach Storage challenges (more reconstitution) Deviates from proven protocols Current recommendation: Stick with proven 10-day cycles for most users Consider continuous only if cyclic approach inadequate Start with standard protocol first Assess your individual response Consult with peptide-knowledgeable physician Use our peptide cycle planning guide to design your Epithalon protocol

Blocking S100A9 binding activity with paquinimod in a murine model of lupus inhibited glomeruli complement deposition and reduced hematuria (130)